NCT05993611View on ClinicalTrials.gov

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

May 21, 2028

Study Completion Date

May 21, 2028

Conditions
Chronic Graft Versus Host DiseaseHematologic and Lymphocytic DisorderSteroid Refractory Graft Versus Host Disease
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given CD6-CAR Tregs IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography

Undergo ECHO

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI/CT

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Tafasitamab

Given IV

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER